このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Fortress Biotech マネジメント

マネジメント基準チェック /34

Fortress Biotech'sの CEO はLindsay Rosenwaldで、 Dec2013年に任命され、の在任期間は 10.5年です。の年間総報酬は$ 1.12Mで、 5.6%給与と94.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の14.43%を直接所有しており、その価値は$ 5.66M 。経営陣と取締役会の平均在任期間はそれぞれ10.3年と8.9年です。

主要情報

Lindsay Rosenwald

最高経営責任者

US$1.1m

報酬総額

CEO給与比率	5.6%
CEO在任期間	10.5yrs
CEOの所有権	14.4%
経営陣の平均在職期間	10.3yrs
取締役会の平均在任期間	8.9yrs

経営陣の近況

Recent updates

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder

Dec 15

Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Dec 15

Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Nov 19

Fortress Biotech EPS misses by $0.02, misses on revenue

Nov 09

CEO報酬分析

Fortress Biotech の収益と比較して、Lindsay Rosenwald の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$63m
Dec 31 2023	US$1m	US$63k	-US$69m
Sep 30 2023	n/a	n/a	-US$78m
Jun 30 2023	n/a	n/a	-US$96m
Mar 31 2023	n/a	n/a	-US$100m
Dec 31 2022	US$1m	US$63k	-US$95m
Sep 30 2022	n/a	n/a	-US$97m
Jun 30 2022	n/a	n/a	-US$93m
Mar 31 2022	n/a	n/a	-US$74m
Dec 31 2021	US$3m	US$60k	-US$65m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$33m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$3m	US$59k	-US$47m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$54m
Mar 31 2020	n/a	n/a	-US$54m
Dec 31 2019	US$1m	US$32k	-US$40m
Sep 30 2019	n/a	n/a	-US$45m
Jun 30 2019	n/a	n/a	-US$51m
Mar 31 2019	n/a	n/a	-US$53m
Dec 31 2018	US$2m	US$31k	-US$73m
Sep 30 2018	n/a	n/a	-US$61m
Jun 30 2018	n/a	n/a	-US$69m
Mar 31 2018	n/a	n/a	-US$72m
Dec 31 2017	US$2m	US$31k	-US$65m

報酬と市場: Lindsayの総報酬 ($USD 1.12M ) は、 US市場 ($USD 667.11K ) の同規模の企業の平均を上回っています。

報酬と収益: Lindsayの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Lindsay Rosenwald (69 yo)

10.5yrs

在職期間

US$1,122,585

報酬

Dr. Lindsay Allan Rosenwald, M.D. serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since Oc...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Lindsay Rosenwald	Executive Chairman	10.5yrs	US$1.12m	14.43% $ 5.4m
David Jin	CFO & Head of Corporate Development	4.1yrs	US$1.32m	0.042% $ 15.5k
Michael Weiss	Executive Vice Chairman of Strategic Development & Director	10.3yrs	US$962.66k	6.76% $ 2.5m
Samuel Berry	General Counsel & Corporate Secretary	5.8yrs	データなし	データなし
George Avgerinos	Senior Vice President of Biologics Operations	11yrs	US$386.49k	0.22% $ 81.7k

10.3yrs

平均在職期間

63.5yo

平均年齢

経験豊富な経営陣: FBIOの経営陣は経験豊富で経験豊富です（平均在職期間は10.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Lindsay Rosenwald	Executive Chairman	14.7yrs	US$1.12m	14.43% $ 5.4m
Michael Weiss	Executive Vice Chairman of Strategic Development & Director	10.5yrs	US$962.66k	6.76% $ 2.5m
Malcolm Hoenlein	Independent Director	10.3yrs	US$45.03k	0.029% $ 10.7k
Stephen Nimer	Scientific Advisor	7yrs	データなし	データなし
Dov Klein	Independent Director	8.9yrs	US$120.06k	0.014% $ 5.1k
William Sandborn	Scientific Advisor	7yrs	データなし	データなし
J. Lobell	Independent Director	18yrs	US$87.57k	0.58% $ 216.3k
Xiaoqin Lu	Director	1.5yrs	US$40.03k	0.016% $ 6.0k
David Elliott	Scientific Advisor	7yrs	データなし	データなし
Joel Weinstock	Scientific Advisor	7yrs	データなし	データなし
Mark Lowdell	Member of Scientific Advisory Board	no data	データなし	データなし
Jimmie Harvey	Independent Director	15.5yrs	US$67.57k	0.025% $ 9.4k

8.9yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: FBIOの取締役会は経験豊富であると考えられます ( 8.9年の平均在任期間)。

Fortress Biotech マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Executive Chairman recently bought US$68k worth of stock

Insufficient new directors

Recent updates

Consensus EPS estimates fall by 93%, revenue upgraded

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

New major risk - Revenue and earnings growth

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Fortress Biotech, Inc. has completed a Composite Units Offering.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

New major risk - Share price stability

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Price target decreased by 8.1% to US$3.55

Consensus revenue estimates fall by 20%

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Consensus revenue estimates increase by 36%

Price target decreased by 13% to US$4.34

Consensus revenue estimates fall by 40%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 16% to US$5.10

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Price target decreased to US$5.92

Executive Chairman recently bought US$68k worth of stock

No longer forecast to breakeven

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insufficient new directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Executive Chairman recently bought US$70k worth of stock

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Consensus revenue estimates fall by 13%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

David Jin is the new finance chief of Fortress Biotech

Price target decreased to US$6.10

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fortress Biotech, Inc. to Report Q1, 2022 Results on May 10, 2022

Fortress Biotech, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$6.60

Forecast breakeven date pushed back to 2024

Insufficient new directors

Consensus revenue estimates fall by 19%

Price target decreased to US$6.60

Forecast breakeven date pushed back to 2024

Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Fortress Biotech, Inc. Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

マネジメント基準チェック /34